Anti BCMA CAR- T Cell Therapy for Adults With Relapsed or Refractory Multiple Myeloma

The mail purpose of this study is to estimate the safety and the efficacy of anti-BCMA CAR- T cell immunotherapy for adults with relapsed or refractory multiple myeloma

Trial Details

NCT ID
NCT07477912
Phase
PHASE1 / PHASE2
Sponsor
Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology
Status
RECRUITING
Cancer Type
Multiple Myeloma
Interventions
  • anti BCMA CAR-T cells
Locations (sample)
  • Minsk, Belarus|53.90019,27.56653

Key Eligibility Criteria

  • Male or female, aged ≥18 years.
  • Willing and able to give written, informed consent.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 2.
  • Relapsed or refractory multiple myeloma according to IMWG criteria with two previous lines of therapy and resistance to proteosome inhibitors and i…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Multiple Myeloma Trials on Trialify →